Reset filter
Keywords
HIV ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
    1. 7.1. Anesthesiology
    1. 7.2. Dermatology
    1. 7.3. ENT
    1. 7.4. Geriatrics
    1. 7.5. Gynecology/Obstetrics
    1. 7.6. Internal Medicine
      1. Hematology
      1. Infectious Diseases
      1. Cardiology/Angiology
      1. Pneumology
      1. Gastroenterology
      1. Nephrology
      1. Endocrinology/Metabolic Diseases
      1. Rheumatology
    1. 7.7. Neurology
    1. 7.8. Ophthalmology
    1. 7.9. Palliative Care
    1. 7.10. Pathology/Forensics
    1. 7.11. Pediatrics
    1. 7.12. Psychiatry/Psychosomatics
    1. 7.13. Radiology
    1. 7.14. Surgery
      1. General/Visceral Surgery
      1. Neurosurgery
      1. Plastic Surgery
      1. Thoracic Surgery
      1. Trauma/Orthopedics
      1. Vascular Surgery
    1. 7.15. Urology
    1. 7.16. Dental Medicine/OMS
Selected data models

You must log in to select data models for download or further analysis.

140 Search results.
Relevance Rating New first Old first

AMC-075 Lymphoma Disease Activity and Measurement Form (L01)

- 10/9/17 - 1 form, 5 itemgroups, 17 items, 1 language
Itemgroups: Header - Lymphoma Disease Activity and Measurement Form, Reporting Period, Nodal Involvement Evaluation, Extra Nodal Involvement Evaluation, Comments
AMC-075 Lymphoma Disease Activity and Measurement Form (L01) Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With Previously Untreated HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9F166B5D-4C13-06F1-E040-BB89AD434FAE

AMC-075 Pharmacodynamics Form (PD1)

- 8/29/17 - 1 form, 3 itemgroups, 8 items, 1 language
Itemgroups: Header - Pharmacodynamics Form, Chemotherapy infusion, Comments
AMC-075 Pharmacodynamics Form (PD1) Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With Previously Untreated HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A0D19232-12FC-67AA-E040-BB89AD43700F

AMC-075 HIV T-Cell Laboratory Values Form (F24)

- 8/24/17 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Header - HIV T-Cell Laboratory Values Form, T-Cell Laboratory Values
AMC-075 HIV T-Cell Laboratory Values Form (F24) Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With Previously Untreated HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9F15665C-2E3D-498C-E040-BB89AD433080

AMC-047 AIDS and Cancer Specimen Resource (ACSR) Procurement Form (F37)

- 8/29/17 - 1 form, 4 itemgroups, 14 items, 1 language
Itemgroups: Header - AIDS and Cancer Specimen Resource (ACSR) Procurement Form, Specimen Procurement, Contact Information, Comments
AMC-047 AIDS and Cancer Specimen Resource (ACSR) Procurement Form (F37) Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=21FA0742-63E9-07A9-E044-0003BA3F9857

AMC-047 HIV Viral Load Form (F40)

- 8/28/17 - 1 form, 3 itemgroups, 9 items, 1 language
Itemgroups: Header - HIV Viral Load Form, HIV Viral Load, Comments
AMC-047 HIV Viral Load Form (F40) Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=21FA0029-D088-0711-E044-0003BA3F9857

AMC-047 HIV T-Cell Laboratory Values Form (F24)

- 8/28/17 - 1 form, 3 itemgroups, 11 items, 1 language
Itemgroups: Header - HIV T-Cell Laboratory Values Form, T-Cell Laboratory Values, Comments
AMC-047 HIV T-Cell Laboratory Values Form (F24) Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=21F8FABF-DDCE-0656-E044-0003BA3F9857

AIDS-Related Lymphoma NCT00310128 Treatment - Study Drug Therapy Form for Protocol #010--PR1003 - 2399688v3.0 - Study Drug Therapy Form for Protocol #010--PR1003

- 1/9/15 - 1 form, 4 itemgroups, 19 items, 1 language
Itemgroups: General info, Body surface, Initial Prescribed Dose of Study Drug, Enter total dose of study drug administered this cycle and dose modification codes
Study Drug Therapy Form for Protocol #010--PR1003 Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FF9311DF-A3A4-2D7C-E034-0003BA3F9857

AMC-048 AIDS and Cancer Specimen Resource (ACSR) Procurement Form (F37)

- 8/28/17 - 1 form, 4 itemgroups, 14 items, 1 language
Itemgroups: Header - AIDS and Cancer Specimen Resource (ACSR) Procurement Form, Specimen Procurement, Contact Information, Comments
AMC-048 AIDS and Cancer Specimen Resource (ACSR) Procurement Form (F37) Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=32E18FA2-31A3-4AF2-E044-0003BA3F9857

AMC-048 HIV Viral Load Form (F40)

- 8/28/17 - 1 form, 3 itemgroups, 9 items, 1 language
Itemgroups: Header - HIV Viral Load Form, HIV Viral Load, Comments
AMC-048 HIV Viral Load Form (F40) Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=32E1BD21-3D3D-538C-E044-0003BA3F9857

Death Form (F04) Lymphoma (NCT00392834)

- 1/8/15 - 1 form, 1 itemgroup, 10 items, 1 language
Itemgroup: Death Information
AMC-048 Death Form (F04) Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma NCT00392834 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=32E18FA2-3312-4AF2-E044-0003BA3F9857

AMC-048 Missed Visit Form (F35) NCT00392834

- 6/3/15 - 1 form, 3 itemgroups, 6 items, 1 language
Itemgroups: Header Module, Missed Visit information, Comments
AMC-048 Missed Visit Form (F35) NCT00392834 Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=32E1BD21-3EC8-538C-E044-0003BA3F9857

dbGaP phs000454 HIV-1 Host Genetics Among Injection Drug Users - Eligibility

- 12/14/22 - 6 forms, 1 itemgroup, 2 items, 1 language
Itemgroup: IG.elig
Principal Investigator: Eric O. Johnson, PhD, RTI International, Research Triangle Park, North Carolina, USA MeSH: HIV,Viral Load,Substance Abuse, intravenous https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000454 The overarching goal of this project is to identify and characterize genetic determinants of HIV 1 susceptibility and resistance in samples of African American (AA) and European American (EA) injection drug users (IDUs) by conducting (1) a case/control genome-wide association (GWA) study of HIV 1 infection (positive/negative); (2) a case-only GWA study of viral load among HIV+ IDUs. The study uses existing samples and data from Urban Health Study (UHS) (PI: Alex Kral), which was the longest-running study of street-recruited IDUs in North America, from 1986-2005. UHS was a serial, cross-sectional sero-epidemiological study. Data were collected every 6 months in communities with a high prevalence of injection drug use in the San Francisco Bay Area. It used targeted sampling in neighborhoods at easily accessible community field sites, such as churches, single room occupancy hotels, and community centers. Eligibility criteria for initial entry to the study were (1) injection drug use in past 30 days; (2) ability to provide informed consent; and (3) age 18 or older. The UHS cohort includes over 9,000 African American and European American IDUs whose serum samples have been stored and data are available on HIV antibody status, HIV risk behaviors, drug abuse and demographics. The current study includes 984 HIV+ cases and 2,243 HIV- controls. Approximately two HIV- controls per case were frequency matched on: (1) self-reported ancestry; (2) sex; (3) age; (4) year of ascertainment; and (5) HIV risk class. This GWAS (DA026141) was funded by the National Institute on Drug Abuse (NIDA; PI: Eric O. Johnson). Funding support for genotyping, which was performed at the Johns Hopkins University Center for Inherited Disease Research (CIDR), was provided by NIDA and the NIH contract "High throughput genotyping for studying the genetic contributions to human disease"(HHSN268200782096C).

pht002648.v1.p1

1 itemgroup 4 items

pht002649.v1.p1

1 itemgroup 5 items

pht002650.v1.p1

1 itemgroup 23 items

pht003326.v1.p1

1 itemgroup 5 items

pht003327.v1.p1

1 itemgroup 5 items

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial